University of Missouri Expands Development of Breakthrough Cancer-Fighting Drugs

Sept. 4, 2025
Contact: Janese Heavin, heavinj@missouri.edu
Photo by Abbie Lankitus

Today, the University of Missouri celebrated the start of construction for two major expansions at the University of Missouri Research Reactor (MURR). These new facilities will boost the production of important radioisotopes needed for treatments, especially for cancer patients.

The expansions will add over 29,000 square feet of space. One section, measuring 11,200 square feet, will have three production lines specifically for lutetium-177, a key ingredient in some cancer-fighting medications. The other, larger addition at 17,900 square feet will increase overall production capacity.

University of Missouri President Mun Choi emphasized the importance of this growth. “We need to meet the rising demand for radioisotopes used in lifesaving treatments. These improvements will help us serve more patients in Missouri and beyond,” he said.

MURR is unique. It’s the only facility in the U.S. that produces four essential medical radioisotopes. These isotopes can treat over a dozen types of cancer, including liver and prostate cancers. This capability is crucial, especially considering the limited time these isotopes remain effective.

Todd Graves, chair of the UM Board of Curators, expressed pride in MURR’s accomplishments and its patient impact: “We’re pushing the boundaries of science and advancing public health. Our expansions are a testament to that commitment.”

Because Missouri is centrally located, medical isotopes from MURR can reach healthcare providers quickly, which is vital due to their short half-lives. Matt Sanford, the executive director of MURR, noted, “We operate year-round, making us a reliable source. The demand is increasing, and these expansions will enable us to meet it.” This continuous operation makes MURR vital for patients needing urgent treatments.

Recent data shows a 12% annual increase in the demand for radioisotopes across the U.S., driven by advancements in treatments like theranostics, which combine therapy and diagnostics. This growth highlights the ongoing need for facilities like MURR to step up and enhance their production capabilities.

The Board of Curators approved these expansions during the April 2024 meeting. As MURR continues to advance, its role in cancer treatment becomes even more critical, illustrating the important link between research and patient care.

Source link